Suppression of humoral immune response to hepatitis B surface antigen vaccine in BALB/C mice by 1-methyl-tryptophan co-administration

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 3, 2011, Pages 236-239

  Eleftheriadis, T ^a,b   Sparopoulou, T ^b   Antoniadi, G ^a   Liakopoulos, V ^a   Stefanidis, I ^a   Galaktidou, G ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

DL 1 MT; IDO; Serum anti HBs

Indexed keywords

1 METHYL TRYPTOPHAN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN;

EID: 80053437070     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167-2172
2. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009; 113: 2394-2401
3. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, Trucco M. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51: 356-365
4. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune infammation. FASEB J 2005; 19: 1347-1349
5. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I, Galaktidou G. Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination. Vaccine 2011; 29: 2242-2247
6. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193
7. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147-1154
8. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2008; 46: 203-211
9. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129: 186-196
10. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74
11. Hou W, Li S, Wu Y, Du X, Yuan F. Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis. Clin Exp Immunol 2009; 156: 363-372
12. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009; 182: 7509-7517